– USA, MA – Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and micro biome platform, today announced that it has closed a Series B investment round with $40 million in additional financing led by OrbiMed HealthCare Fund Management, bringing the total investment in its combined Series A and B financing to $70 million.…
– USA, CA – Adicet Bio, Inc., a biopharmaceutical company focused on the development of next-generation cell immunotherapies, announced today that it closed a $51 million Series A financing.…
– SWITZERLAND, Geneva – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth, today announced the closing of a CHF 60 (USD 60) million Series B preferred equity financing.…
– USA, MA – Avedro, Inc. announced today the successful completion of a $32 million equity financing led by new investors InterWest and OrbiMed which also includes several of the company’s existing investors.…
– USA, CT – Arvinas LLC a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has closed a Series B financing round of $41.6 million.…